- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 12.01. | Aardvark Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 12.01. | Raymond James bestätigt "Strong Buy" für Aardvark Therapeutics mit Kursziel von 47 Dollar | 4 | Investing.com Deutsch | ||
| 12.01. | Raymond James reiterates Strong Buy on Aardvark Therapeutics stock with $47 target | 3 | Investing.com | ||
| AARDVARK THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 23.12.25 | Oppenheimer initiates Aardvark Therapeutics stock with Outperform rating | 2 | Investing.com | ||
| 23.12.25 | Oppenheimer startet Coverage für Aardvark Therapeutics mit "Outperform" | 3 | Investing.com Deutsch | ||
| 12.12.25 | William Blair initiates coverage on Aardvark Therapeutics stock with Outperform rating | 1 | Investing.com | ||
| 12.12.25 | William Blair nimmt Coverage für Aardvark Therapeutics mit "Outperform" auf | 4 | Investing.com Deutsch | ||
| 11.12.25 | Aardvark Therapeutics stock rises 13% on positive trial updates, BTIG maintains Buy | 1 | Investing.com | ||
| 11.12.25 | Raymond James bestätigt Aardvark Therapeutics mit "Strong Buy" und Kursziel von 47 $ | 3 | Investing.com Deutsch | ||
| 11.12.25 | Raymond James reiterates Strong Buy on Aardvark Therapeutics stock with $47 target | 4 | Investing.com | ||
| 10.12.25 | Aardvark Therapeutics, Inc.: Aardvark Therapeutics Announces First Patient Dosed in Australia in HERO Phase 3 Trial for Prader-Willi Syndrome | 153 | GlobeNewswire (Europe) | Multiple active sites and strong US enrollment continue to support Q3 2026 timing for topline data readout Clinical trial sites in Canada and the United Kingdom have received regulatory clearance... ► Artikel lesen | |
| 10.12.25 | Aardvark Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 02.12.25 | Raymond James startet Coverage für Aardvark Therapeutics mit "Strong Buy" und hohem Kurspotenzial | 5 | Investing.com Deutsch | ||
| 02.12.25 | Raymond James initiates coverage on Aardvark Therapeutics stock with Strong Buy | 3 | Investing.com | ||
| 14.11.25 | Stifel reiterates Buy rating on Aardvark Therapeutics stock, maintains $24 target | 1 | Investing.com | ||
| 14.11.25 | Aardvark Therapeutics stock price target lowered to $18 at RBC Capital | 1 | Investing.com | ||
| 13.11.25 | Aardvark Therapeutics, Inc.: Aardvark Therapeutics Reports Third Quarter 2025 Financial Results and Provides Pipeline and Business Updates | 277 | GlobeNewswire (Europe) | Aardvark has aligned with the FDA to reduce the minimum age of eligibility from 13 to 10 years old for pediatric patients in HERO, the Phase 3 trial of ARD-101 for the treatment of hyperphagia associated... ► Artikel lesen | |
| 13.11.25 | Aardvark Therapeutics, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 13.11.25 | Aardvark Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 11.11.25 | Aardvark Therapeutics, Inc.: Aardvark Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4) | 3 | GlobeNewswire (USA) |
1 2 3 Weiter >>
43 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIOCRYST PHARMACEUTICALS | 5,706 | -0,56 % | BioCryst Pharmaceuticals, Inc.: BioCryst Announces Preliminary Full Year 2025 ORLADEYO (berotralstat) Net Revenue of $601 Million (+37 percent y-o-y), Beating Prior Guidance Range | -Excluding European ORLADEYO revenue for the full year 2025, preliminary 2025 ORLADEYO net revenue was $563 million (+43 percent y-o-y on a comparable basis)- -ORLADEYO net revenue expected to be... ► Artikel lesen | |
| MICROBOT MEDICAL | 1,899 | +1,71 % | Microbot Medical Inc. - 8-K, Current Report | ||
| IMMUNITYBIO | 4,789 | +0,55 % | ImmunityBio (IBRX) Rallies on 11th Day, Hits 52-Week High on Strong Clinical Trial Results | ||
| VOYAGER THERAPEUTICS | 3,326 | +2,46 % | Voyager Therapeutics, Inc.: Voyager Reports Third Quarter 2025 Financial and Operating Results | - Momentum building around tau: expect VY7523 clinical data and VY1706 clinical entry in 2026 - - Sharpened focus on multi-modality pipeline with introduction of Voyager NeuroShuttle discovery... ► Artikel lesen | |
| CAPRICOR | 20,500 | -2,38 % | Capricor Therapeutics stock rating reiterated by Cantor Fitzgerald | ||
| ZEVRA THERAPEUTICS | 7,600 | -1,94 % | Zevra Therapeutics Executes Distribution Agreement to Broaden Access to MIPLYFFA for the Treatment of Niemann-Pick Disease Type C (NPC) | CELEBRATION, Fla., Dec. 29, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living... ► Artikel lesen | |
| ABEONA THERAPEUTICS | 4,880 | +7,49 % | Abeona Therapeutics Inc.: Abeona Therapeutics Announces Appointment of Mohamad Tabrizi as Chief Business Officer | CLEVELAND, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced the appointment of Mohamad Tabrizi, M.S., M.B.A., as Senior Vice President, Chief Business Officer... ► Artikel lesen | |
| VIR BIOTECHNOLOGY | 6,065 | -2,18 % | Vir Biotechnology reports promising results for hepatitis delta therapy | ||
| DBV TECHNOLOGIES | 3,650 | -0,95 % | DBV Technologies S.A.: DBV Technologies Announces €166.7 Million in Gross Proceeds Following the Full Exercise of the ABSA Warrants and BS Warrants Issued on its March 2025 Financing | Châtillon, France, January 16, 2026
DBV Technologies Announces €166.7 Million in Gross Proceeds Following the Full Exercise of the ABSA Warrants and BS Warrants Issued on its March 2025 Financing... ► Artikel lesen | |
| PALVELLA THERAPEUTICS | 87,50 | +1,16 % | PALVELLA THERAPEUTICS, INC. - 8-K, Current Report | ||
| MARKER THERAPEUTICS | 1,370 | 0,00 % | Marker Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates | APOLLO study showed encouraging overall responses and favorable safety profile in relapsed/refractory B-cell lymphoma MT-601 demonstrated 66% objective response rate with 50% complete response in... ► Artikel lesen | |
| KALVISTA PHARMACEUTICALS | 12,600 | 0,00 % | KalVista Pharmaceuticals, Inc.: KalVista Pharmaceuticals Provides Update on Strong EKTERLY Launch with Preliminary Fourth Quarter and Full Year 2025 Revenue Results | Approximately $35 million and $49 million unaudited global net product revenue of EKTERLY (sebetralstat) for the fourth quarter and full year 2025, respectively 1,318 patient start forms received... ► Artikel lesen | |
| CARTESIAN THERAPEUTICS | 6,000 | 0,00 % | Cartesian Therapeutics, Inc.: Cartesian Therapeutics Highlights Recent Progress and Outlines 2026 Outlook | Enrollment on track in Phase 3 AURORA trial of Descartes-08 in myasthenia gravis IND application for Descartes-08 in myositis accepted by FDA; seamless adaptive clinical trial offering potential... ► Artikel lesen | |
| QUANTUM-SI | 1,270 | +3,25 % | Quantum-Si Inc - 8-K, Current Report | ||
| PROTARA THERAPEUTICS | 4,340 | +0,46 % | Protara auf Kurs: Zwischenergebnisse zu Blasenkrebsstudie für Q1 2026 erwartet |
AARDVARK THERAPEUTICS INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell +0,13 % bei einem Aktienkurs von 15,370 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu AARDVARK THERAPEUTICS INC finden Sie auf Wallstreet Online.